Business
‘Not for the faint-hearted’: COVID crisis brings boom time for biotechs – Sydney Morning Herald
The pandemic has put the focus on Australia’s biotech sector where high risk, high reward is par for the course and regulators can make or break a company.
Normal text sizeLarger text sizeVery large text size
Mesoblast boss and major shareholder Silviu Itescu wont be the only one breathing easier now that the ASX-listed biotechs flagship treatment has managed to get the green light from the US regulators advisory committee.
It was a close run thing by all accounts and for Itescu and investors in Mesoblast a no vote would have seen a decades worth of work come to a standstill.
For his part, Itescu says he wasnt quite as spooked as investors by si…
-
General22 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News21 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
General23 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
Noosa News24 hours agoWoman left with significant arm injuries in lion attack at Darling Downs Zoo in Queensland